Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2013



Summary



Global Markets Direct’s pharmaceuticals report, “Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2013” provides data on the Takeda Pharmaceutical Company Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Takeda Pharmaceutical Company Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Takeda Pharmaceutical Company Limited and industry-specific third party sources, put together by Global Markets Direct’s team.



Scope


- Takeda Pharmaceutical Company Limited - Brief Takeda Pharmaceutical Company Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Takeda Pharmaceutical Company Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Takeda Pharmaceutical Company Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Takeda Pharmaceutical Company Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.



Reasons to buy


- Evaluate Takeda Pharmaceutical Company Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Takeda Pharmaceutical Company Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Takeda Pharmaceutical Company Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Takeda Pharmaceutical Company Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Takeda Pharmaceutical Company Limited and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Takeda Pharmaceutical Company Limited Snapshot 6
Takeda Pharmaceutical Company Limited Overview 6
Key Information 6
Key Facts 6
Takeda Pharmaceutical Company Limited - Research and Development Overview 7
Key Therapeutic Areas 7
Takeda Pharmaceutical Company Limited - Pipeline Review 15
Pipeline Products by Stage of Development 15
Pipeline Products - Monotherapy 16
Pipeline Products - Combination Treatment Modalities 17
Takeda Pharmaceutical Company Limited - Pipeline Products Glance 18
Takeda Pharmaceutical Company Limited - Late Stage Pipeline 18
Takeda Pharmaceutical Company Limited Clinical Stage Pipeline Products 21
Takeda Pharmaceutical Company Limited - Early Stage Pipeline Products 23
Takeda Pharmaceutical Company Limited - Drug Profiles 25
2-CB 25
alogliptin benzoate 26
AMG-557 27
Arginine Methyltrasferase Programme 28
azilsartan medoxomil 29
BTZO-2 30
ceftaroline fosamil 31
cetilistat 32
Compound 19b 33
Compound-3a 34
Compound-3t 35
Compound-54 36
Compound-60j 37
dexlansoprazole 38
Drugs Targeting Neddylation 39
fasiglifam 40
Focal Adhesion Kinase Inhibitor 41
Focal Adhesion Kinase Inhibitors 42
fomepizole 43
fulranumab 44
ganitumab 45
Haemophilus influenzae type b conjugate vaccine 46
idebenone 47
ITI-214 48
Kanda Human Papillomavirus Vaccine 49
lubiprostone 50
lurasidone hydrochloride 51
mapatumumab 52
MLN-1202 53
motesanib diphosphate 54
peginesatide 55
prepandemic influenza vaccine (A/H5N1) (whole virion, vero cell derived, inactivated) 56
Program 1 For Parkinson's Disease 57
Program 5 For Parkinson's Disease 58
Program For Diabetes And Obesity 59
ramelteon 60
RNAi Therapeutics Program 61
TAK-063 62
TAK-272 63
TAK-329 64
TAK-361S 65
TAK-385 66
TAK-428 67
tedatioxetine 68
trebananib 69
trelagliptin 70
vedolizumab 71
veltuzumab 72
vonoprazan 73
vortioxetine 74
Y-142 75
Takeda Pharmaceutical Company Limited - Pipeline Analysis 76
Takeda Pharmaceutical Company Limited - Pipeline Products by Therapeutic Class 76
Takeda Pharmaceutical Company Limited - Pipeline Products By Target 80
Takeda Pharmaceutical Company Limited - Pipeline Products by Route of Administration 81
Takeda Pharmaceutical Company Limited - Pipeline Products By Mechanism of Action 82
Takeda Pharmaceutical Company Limited - Recent Pipeline Updates 84
Takeda Pharmaceutical Company Limited - Dormant Projects 113
Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products 117
Discontinued Pipeline Product Profiles 118
Takeda Pharmaceutical Company Limited - Company Statement 128
Takeda Pharmaceutical Company Limited - Locations And Subsidiaries 133
Head Office 133
Other Locations and Subsidiaries 133
Takeda Pharmaceutical Company Limited - Key Manufacturing Facilities 139
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 141
Disclaimer 141

List of Tables

Takeda Pharmaceutical Company Limited, Key Information 10
Takeda Pharmaceutical Company Limited, Key Facts 10
Takeda Pharmaceutical Company Limited - Pipeline by Indication, 2013 14
Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2013 19
Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2013 20
Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2013 21
Takeda Pharmaceutical Company Limited - Filing rejected/Withdrawn, 2013 22
Takeda Pharmaceutical Company Limited - Phase III, 2013 23
Takeda Pharmaceutical Company Limited - Phase II, 2013 25
Takeda Pharmaceutical Company Limited - Phase I, 2013 26
Takeda Pharmaceutical Company Limited - Preclinical, 2013 27
Takeda Pharmaceutical Company Limited - Discovery, 2013 28
Takeda Pharmaceutical Company Limited - Pipeline By Therapeutic Class, 2013 81
Takeda Pharmaceutical Company Limited - Pipeline By Target, 2013 84
Takeda Pharmaceutical Company Limited - Pipeline By Route of Administration, 2013 85
Takeda Pharmaceutical Company Limited - Pipeline Products By Mechanism of Action, 2013 87
Takeda Pharmaceutical Company Limited - Recent Pipeline Updates, 2013 88
Takeda Pharmaceutical Company Limited - Dormant Developmental Projects,2013 117
Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products, 2013 121
Takeda Pharmaceutical Company Limited, Subsidiaries 137
Takeda Pharmaceutical Company Limited, Key Manufacturing Facilities 143

List of Figures

Takeda Pharmaceutical Company Limited - Pipeline by Indication, 2013 14
Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2013 19
Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2013 20
Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2013 21
Takeda Pharmaceutical Company Limited - Pipeline By Therapeutic Class, 2013 80
Takeda Pharmaceutical Company Limited - Pipeline By Route of Administration, 2013 85
Takeda Pharmaceutical Company Limited - Pipeline Products By Mechanism of Action, 2013 86

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Adalimumab  - Comprehensive patent search

Adalimumab - Comprehensive patent search

  • $ 10 118
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are ...

Amphotericin B  - Comprehensive patent search

Amphotericin B - Comprehensive patent search

  • $ 10 118
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are ...

Bemiparin sodium  - Comprehensive patent search

Bemiparin sodium - Comprehensive patent search

  • $ 10 118
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.